Impact of anti-orthopoxvirus neutralizing antibodies induced by a heterologous prime-boost HIV-1 vaccine on insert-specific immune responses.
Vaccine
; 31(1): 114-9, 2012 Dec 17.
Article
en En
| MEDLINE
| ID: mdl-23142302
ABSTRACT
BACKGROUND:
The impact of anti-vector immunity on the elicitation of insert-specific immune responses is important to understand in vaccine development. HVTN 055 was a 150 person phase I randomized, controlled HIV vaccine trial of recombinant modified vaccinia Ankara (rMVA) and fowlpox (rFPV) with matched HIV-1 inserts which demonstrated increased CD8+ T-cell immune responses in the heterologous vaccine group. The controls used in this study were the empty vectors (MVA and FPV).METHODS:
Anti-MVA and anti-vaccinia neutralizing antibodies (NAbs) were measured and compared with cellular and humoral HIV-1-specific immune responses.RESULTS:
Elicitation of anti-vector responses increased with increasing dose of MVA and up to 2 administrations. Further inoculations of MVA (up to 5) did not increase the magnitude of the anti-MVA response but did delay the anti-vector NAb titre decay. There was no evidence that the insert impaired the anti-vector response, nor that anti-vector immunity attenuated the insert-specific responses.CONCLUSION:
Two doses of MVA may be ideal for the elicitation of orthopoxvirus immune responses with further doses maintaining increased titres against the vector. We found no evidence that eliciting HIV insert- or MVA vector-specific immune responses interfered with elicitation of immune responses to the other.
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Vacunas contra el SIDA
/
Orthopoxvirus
/
Anticuerpos Neutralizantes
Tipo de estudio:
Clinical_trials
Límite:
Humans
Idioma:
En
Revista:
Vaccine
Año:
2012
Tipo del documento:
Article
País de afiliación:
Estados Unidos